← Leaderboards
Crystal Mackall
Children'S Hosp Of Philadelphia
$19,988,621
Attributed
$24,950,597
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $23M · FY2018–25$25M$18.8M$12.5M$6.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$37,850,880 · 11
By mechanism
U54$23,686,016 · 2
R01$3,294,656 · 1
UG3$2,781,440 · 1
P01$2,040,567 · 3
OT2$2,019,991 · 1
R35$1,863,847 · 1
Top collaborators
- Michelle Monje-Deisseroth5 shared
- John M Maris4 shared
- Sabine Heitzeneder3 shared
- Steven A Feldman2 shared
- Olivier Gevaert2 shared
Most similar at Children'S Hosp Of Philadelphia
Same institution · by research overlap
- Pamela Fitch Weiss$3,661,080
- John M Maris$30,818,378
- Robbie G. Majzner$6,350,674
- Eric Chien-Wei Liao$8,908,460
- Kristina Ann Cole$1,757,336
Others in their field
Other Emerging Leaders on “Malignant Neoplasms”
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
- Leonard Freedmand · Leidos Biomedical Research, Inc.$108,968,336
- Beverly Hayes · Leidos Biomedical Research, Inc.$98,336,166
- Martha Hering · Westat, Inc.$57,098,843
Research focus
Malignant NeoplasmsTumorImmunotherapyT-LymphocyteAntigensEngineeringChimeric Antigen Receptor T CellsMediatingToxic EffectDesignTranslatingChildCellsResistanceRegimenExhaustionCar T Cell TherapyChildhoodChimeric Antigen ReceptorPreventBrain NeoplasmsDoseSolid NeoplasmAntitumor Effect
Grant awards (29)
Multimodal AI modeling of T cell therapies to predict patient response and nominate advanced cell design strategies$1,673,650
OT2 · FY2025 · OD · contact PI
Next Generation GPC2-CARs for Medulloblastoma$1,390,720
UG3 · FY2025 · CA · contact PI
Next Generation Immunotherapies for Pediatric Cancers$932,006
R35 · FY2025 · CA · contact PI
Attacking the Immunopeptidome of Ewing Sarcoma$697,731
U01 · FY2025 · CA · contact PI
Developing Safe and Effective GD2-CAR T Cell Therapy for Diffuse Midline Gliomas$660,052
R01 · FY2025 · CA · contact PI
Designing Chimeric Antigen Receptor Therapies to Overcome Treg Suppression$464,334
P01 · FY2025 · CA · contact PI
Multimodal AI modeling of T cell therapies to predict patient response and nominate advanced cell design strategies$346,341
OT2 · FY2025 · OD · contact PI
Cancer Immunotherapy$169,872
P30 · FY2025 · CA · contact PI
Next Generation GPC2-CARs for Medulloblastoma$1,390,720
UG3 · FY2024 · CA · contact PI
Next Generation Immunotherapies for Pediatric Cancers$931,841
R35 · FY2024 · CA · contact PI
Attacking the Immunopeptidome of Ewing Sarcoma$662,764
U01 · FY2024 · CA · contact PI
Developing Safe and Effective GD2-CAR T Cell Therapy for Diffuse Midline Gliomas$660,339
R01 · FY2024 · CA · contact PI
Cancer Immunotherapy$55,542
P30 · FY2024 · CA · contact PI
Developing Safe and Effective GD2-CAR T Cell Therapy for Diffuse Midline Gliomas$658,390
R01 · FY2023 · CA · contact PI
Attacking the Immunopeptidome of Ewing Sarcoma$467,370
U01 · FY2023 · CA · contact PI
Project 4: Enhancing the Efficacy of Chimeric Antigen Receptor Therapy for B-ALL and DLBCL$316,522
P01 · FY2023 · CA · contact PI
Cancer Immunotherapy$55,542
P30 · FY2023 · CA · contact PI
Developing Safe and Effective GD2-CAR T Cell Therapy for Diffuse Midline Gliomas$644,430
R01 · FY2022 · CA · contact PI
Project 4: Enhancing the Efficacy of Chimeric Antigen Receptor Therapy for B-ALL and DLBCL$310,192
P01 · FY2022 · CA · contact PI
Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers$264,000
U54 · FY2022 · CA
Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers$255,100
U54 · FY2022 · CA
Cancer Immunotherapy$55,542
P30 · FY2022 · CA · contact PI
Developing Safe and Effective GD2-CAR T Cell Therapy for Diffuse Midline Gliomas$671,445
R01 · FY2021 · CA · contact PI
Project 4: Enhancing the Efficacy of Chimeric Antigen Receptor Therapy for B-ALL and DLBCL$316,522
P01 · FY2021 · CA · contact PI
Project 4: Enhancing the Efficacy of Chimeric Antigen Receptor Therapy for B-ALL and DLBCL$316,509
P01 · FY2020 · CA · contact PI
Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers$184,000
U54 · FY2020 · CA
Project 4: Enhancing the Efficacy of Chimeric Antigen Receptor Therapy for B-ALL and DLBCL$316,488
P01 · FY2019 · CA · contact PI
Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers$12,197,183
U54 · FY2018 · CA
Understanding and Overcoming Resistance to Immunotherapies in Childhood Cancers$10,785,733
U54 · FY2018 · CA · contact PI